Table 2. The treatment characteristic and clinical outcome during follow-up.
| Author | Follow-up (months)† | Time (min)† | NPVR (%)† | Duration of hospitalization (days), mean | Symptom relief (n) | Complication (n) | Complete response (n) | Local control rate (%) | Repeated treatment (n) | Anesthesia (general/local and others) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Minor | Major | ||||||||||
| Kujak et al. (18) | 32.4±22.5 | NR | NR | NR | 3 | 2 | 0 | 2 | 60.00 | NR | NR |
| Wang et al. (19) | 29.9±17.9 | NR | NR | 3 | NR | 9 | 1 | 2 | 100.00 | 2 | 25/0 |
| Havez et al. (20) | 11.3±7.2 | NR | NR | 1.5 | 14 | 3 | 0 | 1 | 88.24 | NR | 15/2 |
| Schmitz et al. (23) | 16.2±20 | NR | NR | 1.4 | 4 | 3 | 0 | 10 | 91.30 | NR | NR |
| Avedian et al. (22) | 18.2±4.6 | 270±87 | 65.2±32.1 | NR | NR | 5 | 0 | 1 | 60.00 | 3 | 3/2 |
| Zhao et al. (21) | 14.6±2.2 | 74±31 | 92.5±3.7 | 7 | 7 | 3 | 1 | 0 | 100.00 | 1 | 0/7 |
| Ghanouni et al. (24) | 17.6±10.6 | 210±96 | 79.1±22.1 | 0.12 | 6 | 8 | 2 | 5 | 96.00 | 7 | 15/17 |
| Najafi et al. (25) | 27.0±19.2 | NR | NR | NR | NR | 4 | 0 | 3 | 100.00 | 3 | 0/5 |
| Redifer Tremblay et al. (26) | 16.8±10.4 | 173±46 | 71.3±26.5 | 0.23 | 18 | 4 | 2 | 5 | 86.67 | 4 | 13/17 |
| Bouhamama et al. (28) | NR | NR | NR | NR | NR | 4 | 0 | 14 | 51.22 | NR | 23/18 |
| Saltiel et al. (27) | 53.8±23.1 | NR | 67.3±30.2 | NR | NR | 0 | 2 | 3 | 85.71 | 4 | NR |
| Mandel et al. (32) | NR | NR | NR | 1.3 | 5 | 7 | 1 | NR | 59.09 | 5 | 22/0 |
| Kurtz et al. (30) | NR | NR | NR | 4 | NR | 31 | 11 | NR | NR | 6 | 50/0 |
| Auloge et al. (13) | 31.9±25.6 | NR | 71.7±27.0 | 2 | 29 | 7 | 4 | 13 | NR | 7 | 30/0 |
| Zhang et al. (12) | NR | 116±59 | 81.9±18.7 | 3 | NR | 61 | 3 | NR | NR | 8 | 9/177 |
| Efrima et al. (31) | NR | NR | 72.1±20.0 | 3 | 9 | 3 | 0 | 1 | NR | 9 | 16/0 |
| Yan et al. (29) | 18.5±21.3 | 132±51 | 81.5±25.6 | 1.7 | 32 | 3 | 1 | 0 | 88.46 | 10 | 37/4 |
| Martínez-Martínez et al. (14) | 3.8±1.9 | NR | NR | NR | 8 | 1 | 1 | 2 | 77.78 | 11 | NR |
| Zhong et al. (33) | 32.7±20.3 | NR | 69.5±23.8 | NR | NR | 28 | 7 | 12 | 96.70 | NR | 122/0 |
| Johnston et al. (36) | 13.9±20.3 | 112±40 | NR | 2.0 | NR | 8 | 1 | 1 | 70.00 | NR | NR |
| Colak et al. (35) | ≥3.0 | NR | NR | NR | NR | 0 | 0 | NR | 100.00 | 0 | NR |
| Mo et al. (34) | NR | 20±11 | 72.4±22.6 | 3.0 | NR | 42 | 0 | NR | NR | NR | 3/39 |
| Yang et al. (37) | 29.2±15.7 | NR | 71.1±22.9 | NR | NR | 3 | 2 | 1 | 93.30 | 15 | 15/0 |
Complete response is defined according to the RECIST or mRECIST criteria. †, data are presented as mean ± SD. NPVR, non-perfused volume rate; n, number; NR, not reported; RECIST, Response Evaluation Criteria In Solid Tumors; mRECIST, modified RECIST; SD, standard deviation.